Kwality Pharmaceuticals Ltd
Incorporated in 1983, Kwality Pharma is in the business of manufacturing & trading in Pharmaceuticals & allied products[1]
- Market Cap ₹ 526 Cr.
- Current Price ₹ 507
- High / Low ₹ 545 / 248
- Stock P/E 18.5
- Book Value ₹ 206
- Dividend Yield 0.00 %
- ROCE 18.5 %
- ROE 16.5 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 46.7% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 45.2%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Debtor days have increased from 72.0 to 107 days.
- Working capital days have increased from 116 days to 212 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
38 | 62 | 60 | 52 | 76 | 95 | 137 | 165 | 138 | 261 | 456 | 251 | 284 | |
36 | 58 | 56 | 49 | 70 | 86 | 125 | 149 | 124 | 231 | 284 | 190 | 227 | |
Operating Profit | 2 | 3 | 4 | 4 | 6 | 9 | 12 | 15 | 14 | 29 | 172 | 61 | 57 |
OPM % | 5% | 5% | 6% | 7% | 8% | 9% | 8% | 9% | 10% | 11% | 38% | 24% | 20% |
1 | 0 | 0 | 1 | 0 | 2 | 1 | 1 | 4 | 2 | 4 | -14 | -14 | |
Interest | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 3 | 7 | 9 |
Depreciation | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 3 | 4 | 6 | 11 | 15 | 19 |
Profit before tax | 1 | 2 | 2 | 2 | 3 | 6 | 8 | 11 | 11 | 22 | 162 | 26 | 16 |
Tax % | 39% | 27% | 47% | 29% | 39% | 41% | 38% | 31% | 24% | 29% | 26% | 24% | |
1 | 1 | 1 | 1 | 2 | 3 | 5 | 8 | 8 | 15 | 120 | 19 | 12 | |
EPS in Rs | 0.86 | 1.66 | 0.95 | 1.32 | 1.89 | 3.31 | 4.51 | 7.28 | 8.12 | 14.86 | 115.70 | 18.76 | 11.61 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 9% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 15% |
5 Years: | 13% |
3 Years: | 22% |
TTM: | 15% |
Compounded Profit Growth | |
---|---|
10 Years: | 39% |
5 Years: | 47% |
3 Years: | 56% |
TTM: | -24% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 65% |
3 Years: | 78% |
1 Year: | 38% |
Return on Equity | |
---|---|
10 Years: | 35% |
5 Years: | 41% |
3 Years: | 45% |
Last Year: | 16% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 4 | 4 | 4 | 4 | 5 | 5 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Reserves | 7 | 8 | 13 | 15 | 18 | 21 | 21 | 28 | 37 | 52 | 172 | 192 | 203 |
10 | 6 | 6 | 8 | 13 | 19 | 26 | 28 | 35 | 41 | 54 | 90 | 91 | |
11 | 11 | 12 | 10 | 17 | 27 | 41 | 40 | 53 | 65 | 106 | 71 | 54 | |
Total Liabilities | 32 | 29 | 35 | 38 | 52 | 72 | 98 | 107 | 135 | 169 | 343 | 364 | 358 |
9 | 10 | 11 | 11 | 11 | 16 | 19 | 28 | 42 | 56 | 91 | 120 | 135 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 12 | 14 | 0 |
Investments | 1 | 1 | 3 | 4 | 5 | 7 | 9 | 8 | 8 | 9 | 4 | 4 | 4 |
22 | 18 | 21 | 23 | 36 | 50 | 70 | 71 | 86 | 102 | 236 | 226 | 220 | |
Total Assets | 32 | 29 | 35 | 38 | 52 | 72 | 98 | 107 | 135 | 169 | 343 | 364 | 358 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0 | 8 | -0 | 1 | -3 | 4 | -0 | 12 | 6 | 26 | 59 | 42 | |
-1 | -1 | -4 | -1 | -2 | -7 | -6 | -11 | -17 | -23 | -63 | -48 | |
1 | -5 | 3 | 1 | 5 | 5 | 5 | -2 | 12 | 1 | 6 | 1 | |
Net Cash Flow | -0 | 2 | -2 | 0 | 0 | 1 | -1 | -1 | 1 | 4 | 2 | -5 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 82 | 42 | 41 | 63 | 95 | 87 | 99 | 86 | 80 | 53 | 57 | 107 |
Inventory Days | 114 | 33 | 58 | 61 | 54 | 72 | 54 | 34 | 94 | 38 | 97 | 310 |
Days Payable | 93 | 31 | 58 | 40 | 61 | 67 | 79 | 52 | 96 | 58 | 63 | 117 |
Cash Conversion Cycle | 104 | 44 | 41 | 85 | 89 | 92 | 74 | 68 | 78 | 33 | 91 | 300 |
Working Capital Days | 102 | 35 | 60 | 81 | 87 | 79 | 76 | 62 | 99 | 48 | 89 | 212 |
ROCE % | 13% | 14% | 12% | 11% | 15% | 19% | 19% | 21% | 18% | 26% | 97% | 18% |
Documents
Announcements
- KWALITY PHARMA RECEIVED INVIMA APPROVAL FOR ITS AMPOULE AND VIAL PRODUCT LINES 22 Apr
-
Compliance Certificate For The Year Ended On 31St March, 2024
12 Apr - Compliance certificate under Reg. 7 (3) of SEBI Regulations for year ended 31st March 2024
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
12 Apr - Certificate under Reg 74(5) of SEBI (DP) Regulations for q.e. 31-03-2024 is enclosed herewith
- Certificate Under Regulation 74(5) Of SEBI (Depositories And Participants) Regulations, 2018 For The Quarter Ended March 31, 2024 12 Apr
- Disclosure Of Non-Applicability Of SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 Dated 26Th November, 2018- Fund Raising By Issuance Of Debt Securities By Large Corporate (LC) 11 Apr
Business Overview:[1][2]
KPL is in an ANVISA and EU GMP certified manufacturer of all pharma products including complex molecules across all dosage forms including niche Biologics. It has a portfolio of 3000+ formulations across 25+ therapeutic areas with categories including generics, cephalosporin, beta-lactam, oncology & biologics. It manufactures and deals in drugs intermediates, chemicals, extracts, alkaloids and other pharmaceutical goods, toilet requisites, medicines, beverages and other medical preparations